Compare PMT & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMT | GERN |
|---|---|---|
| Founded | 2009 | 1990 |
| Country | United States | United States |
| Employees | 7 | 258 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 915.6M | 821.1M |
| IPO Year | N/A | N/A |
| Metric | PMT | GERN |
|---|---|---|
| Price | $10.53 | $1.27 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 3 |
| Target Price | ★ $13.50 | $2.17 |
| AVG Volume (30 Days) | 975.2K | ★ 14.2M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 13.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $26.91 |
| Revenue Next Year | $1.55 | $43.75 |
| P/E Ratio | $12.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.23 | $1.04 |
| 52 Week High | $13.80 | $2.01 |
| Indicator | PMT | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 35.38 | 32.94 |
| Support Level | N/A | $1.24 |
| Resistance Level | $12.82 | $1.29 |
| Average True Range (ATR) | 0.28 | 0.09 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 16.04 | 10.42 |
PennyMac Mortgage Investment Trust is a specialty finance company that invests mainly in residential mortgage loans and mortgage-related assets. The company's operations include activities such as the production and servicing of financial securities based on residential loans and the pooling and reselling of high-credit-quality mortgages. The company operates through three segments: correspondent production, credit-sensitive strategies, interest-rate-sensitive strategies. The Credit sensitive strategies segment generates income via investments in CRT arrangements, subordinate MBS, distressed loans, and real estate.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.